Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection

Article information

J Liver Cancer. 2020;20(1):90-97

Publication date (electronic) : 2020 March 31

doi : https://doi.org/10.17998/jlc.20.1.90

Jesang Yu, Jinhong Jung, Sang Min Yoon

Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Corresponding author : Sang Min Yoon Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel. +82-2-3010-5615, Fax. +82-2-3010-6950 E-mail; drsmyoon@amc.seoul.kr

Received 2020 January 18; Revised 2020 February 22; Accepted 2020 February 25.

Abstract

INTRODUCTION

Symptoms related with hepatocellular carcinoma (HCC) are usually affected by the location of the tumor along with its size. As the patients with small HCC do not commonly have self-conscious symptoms, around 10% of patients are diagnosed with huge HCC (≥10 cm) at their initial presentation [1]. Although surgery has been widely used as a potential curative treatment option, most huge HCC patients showed a poor prognosis in previous reported studies [1-8]. Moreover, patients with huge HCC are often considered unresectable owing to the difficulty of complete resection or insufficient remnant liver volume [9]. Therefore, the optimal treatment strategy for unresectable huge HCC has not yet been established. Any single modality, with the exception of hepatic resection, is unable to provide sufficient local tumor control [10-12]. Combined locoregional treatments can be effective options because of the expected synergistic effects in selected cases [13,14]. Here, we have presented a case of a patient with recurrent huge HCC who was treated with combined transarterial chemoembolization (TACE) and external beam radiotherapy. Further, we have presented the patient’s long-term clinical outcomes. In accordance with the regulations, no Institutional Review Board approval was needed for this report.

CASE REPORT

A 58-year-old male patient was referred to our hospital in August 2006 because a regular health examination revealed elevated an alpha-fetoprotein (AFP) level. He had a history of hepatitis B virus infection. The initial laboratory findings were as follows: platelet count 156 × 10³/L, serum albumin 3.8 g/dL, aspartate transaminase 32 IU/L, alanine transaminase 41 IU/L, alkaline phosphatase 80 IU/L, total bilirubin 0.8 mg/dL, prothrombin time 13.2 seconds, and international normalized ratio 1.08. The AFP level was 2,160 ng/mL. A contrast-enhanced liver dynamic computed tomography (CT) scan revealed a 3.5 cm hepatic mass across segments 8 and 4, which had a solid portion on the medial side of the tumor with a non-enhancing cystic portion on the lateral aspect. Although the enhancement of the solid portion was not strongly observed in the arterial phase, subtle washout and capsule enhancement were observed in the delayed phase. Considering all the findings, this tumor was diagnosed clinically as an HCC. The patient received hepatic resection (central bi-segmentectomy) on October 23, 2006 and the mass was diagnosed as a 4.5 × 4.3 × 2.5-cm, multinodular confluent-type HCC (the Edmondson-Steiner grade 3/3) on pathologic examination. During the regular follow-up period, a recurrent HCC measuring 3 cm in segment 3 was observed on liver dynamic CT at 4 years after surgery. However, the patient refused further work-up or management at that time.

Six months later, the patient revisited the outpatient clinic and was examined by another liver dynamic CT (Fig. 1A). The recurrent tumor in segment 3 had increased up to 11 cm in size, and an additional 1.7 cm recurrent HCC in segment 6 was also observed. Through discussion with the multidisciplinary liver cancer team, TACE was performed for the two recurrent HCCs as the first salvage treatment. One month after the first TACE, compact uptake of iodized oil was observed in a small HCC in segment 6, but partial iodized oil uptake in the recurrent HCC in segment 3. After the second TACE (Fig. 1B), external beam radiotherapy was performed for the recurrent HCC in segment 3. The target volume was defined as the recurrent HCC, including both viable and iodized oil uptake area, with additional margin for respiratory motion and set-up errors (Fig. 1C). A total dose of 30 Gy in 12 fractions (equivalent dose in 2 Gy fractions [EQD2], α/β = 10: 31.2 Gy) was delivered with a respiratory gated three-dimensional conformal radiotherapy (3D-CRT) technique using a Real-time Position Management gating system (Varian Medical Systems, Palo Alto, CA, USA). The patient underwent three rounds of additional TACE after radiotherapy. No definitive viable HCC was observed in the liver during the follow-up period (Fig. 1D-H).

Figure 1.

Serial liver dynamic computed tomography (CT) images from the time of recurrence to the last follow-up at 8.6 years. (A) a recurrent hepatocellular carcinoma (HCC) measuring 11 cm (yellow arrowheads) in segment 3 was observed on the arterial phase. (B) Partial iodized oil uptake in recurrent HCC was observed on the follow-up CT scan 1 month after the first TACE. (C) Iso-dose lines of radiotherapy for the recurrent HCC on the planning CT. Total dose (30 Gy in 12 fractions) was prescribed with 97% iso-dose line. (D) After TACE (a total of 5 times) and radiotherapy, no definitive viable HCC was observed. Follow-up CT images at 1 year (E), 2 years (F), 3 years (G), 5 years (H), and 8.4 years (I) after radiotherapy.

At 16 months after completion of radiotherapy for the HCC in segment 3, the patient complained of pain in the right pelvis. Serum levels of AFP and protein induced by vitamin K absence or antagonist II (PIVKA-II) had increased to 187.8 ng/mL and 5,658 mAU/mL, respectively. On a positron emission tomography-CT (PET-CT), a substantial osteolytic lesion showing a heterogenous hypermetabolic mass (maximum standardized uptake value [SUV]: 11.2) was observed in the right iliac bone (Fig. 2A, B). As this is a solitary extrahepatic metastasis without intrahepatic recurrence, high-dose radiotherapy was planned for this metastatic lesion after discussion with the multidisciplinary liver cancer team. A total of 60 Gy in 24 fractions (EQD2: 62.5 Gy) was delivered in the right iliac bone mass using the 3D-CRT technique (Fig. 2C). The pain was no longer present at 3 months after completion of radiotherapy and a markedly decreased enhancing mass was observed on the follow-up CT (Fig. 2D). Serum AFP and PIVKA-II levels had declined; they were within normal limits (2.3 ng/mL and 17 mAU/mL, respectively) 3 months after radiotherapy. Pathologic fractures at the site of bone destruction by the metastatic tumor in the right iliac bone with shrinkage of the tumor was observed on the follow-up CT at 2 years after radiotherapy (Fig. 2E, F); however, the patient was able to walk without any pain or claudication. No recurrence was observed in the right iliac bone during the follow-up period (Fig. 2G, H).

Figure 2.

(A, B) Positron emission tomography-computed tomography scan showing a huge osteolytic lesion with maximum standardized uptake value of 11.2 in the right iliac bone. (C) Iso-dose lines of 3-dimensional conformal radiotherapy for the right iliac bone mass on the planning CT. Total dose (60 Gy in 24 fractions) was prescribed with 97% iso-dose line. (D) Follow-up CT at 3 months after radiotherapy showed a marked decreasing in the enhancing mass. (E) Additional shrinkage of the tumor was observed at 1-year follow-up CT. (F) Two years after radiotherapy, pathologic fractures at the site of bone destruction by the metastatic tumor in the right iliac bone (yellow arrows) were observed. No recurrence was observed on right iliac bone at 3 years (G), 5 years (H), or 6.8 years (I) after radiotherapy.

At 3 years and 6 months after radiotherapy for the HCC in segment 3 of the liver, a lung nodule was detected in the right middle lobe on a follow-up liver dynamic CT (Fig. 3A). Chest CT and PET-CT, performed to confirm the metastasis, revealed a single, hypermetabolic lesion measuring 1 cm (maximum SUV: 11.8) (Fig. 3B). Tumor markers were not elevated at this time (AFP: 2 ng/mL, PIVKA-II: 19 mAU/mL). Stereotactic body radiotherapy (SBRT) of 60 Gy in 4 fractions (EQD2: 125 Gy) was performed for this right middle lobe nodule (Fig. 3C) using volumetric-modulated arc therapy technique. After 3 months of SBRT, a focal radiation pneumonitis without viable tumor was found on a chest CT scan (Fig. 3D). During this follow-up period, a fibrotic change without recurrence, induced by radiation, was observed (Fig. 3E-H). All radiotherapies were delivered with linear accelerators (Varian Medical Systems) and each radiation dose was determined based on the guidelines for organs at risk including the normal liver, stomach, duodenum, large bowel, lung, or spinal cord [15-17].

Figure 3.

Chest computed tomography (CT) (A) and positron emission tomography-CT (B) scans showing a hypermetabolic metastatic nodule with a maximum standardized uptake value of 11.8 (yellow arrowheads) in the right middle lobe. (C) Iso-dose lines of stereotactic body radiotherapy for lung metastasis on the planning CT. Total dose (60 Gy in 4 fractions) was prescribed with 97% iso-dose line. (D) After 3 months of stereotactic body radiotherapy, a focal radiation pneumonitis (yellow arrows) without a viable tumor was found. Radiation induced fibrotic changes without recurrence were observed at 1 year (E), 2 years (F), 3 years (G), 4 years (H), and 5 years (I) after radiotherapy.

By the last follow-up examinations (August 27, 2019), no recurrences were observed at any of the locations, including intrahepatic region (Fig. 1I), right pelvic bone (Fig. 2I), right middle lobe nodule (Fig. 3I). Fig. 4 summarizes the treatments and the trends of AFP levels during the 13 years after the initial diagnosis of HCC.

Figure 4.

Summary of treatments with the trends of alpha-fetoprotein levels from the initial diagnosis to the last follow-up. TACE, transarterial chemoembolization; RT, radiotherapy; HCC, hepatocellular carcinoma; SBRT, stereotactic body radiotherapy.

DISCUSSION

The diagnosis of an unresectable huge HCC shows a poor prognosis as tumor size is an important prognostic factor for survival outcomes in patients with HCC [4,18]. A multi-modality approach could be considered for better clinical outcomes in this clinical situation, however, there has been no clear evidence supporting the use of combined treatment in patients with huge HCC. Complete uptake of iodized oil is not usually observed even after repeated TACE for huge HCC [19-22]; therefore, radiotherapy for residual viable HCC after incomplete TACE can be an effective treatment option [13,19,21,23-27]. Table 1 summarizes the literature on combined TACE and radiotherapy in patients with large HCC (≥5 cm). In the present case, we performed combined TACE (a total of 5 times) and radiotherapy for a recurrent HCC measuring 11 cm. Although a high dose could not be prescribed owing to the proximity of the radiosensitive gastrointestinal organs, long-term local tumor control was achieved over the 8 years of follow-up.

Table 1.

Summary of the results of combined transarterial chemoembolization and radiotherapy in large (≥5 cm) hepatocellular carcinomas

The incompletely responding tumor burden in the liver can also be a source of extrahepatic metastasis. The bone is the most frequent metastatic site from HCC, followed by the lung and lymph nodes [28,29]. In the present case, extrahepatic metastases occurred in the right iliac bone and the lung during the follow-up period. Bone metastasis from HCC typically show a soft tissue mass formation with osteolytic bone changes. Symptoms related with local mass effects can hinder the patients’ quality of life (QoL) [30-32]. There have been multiple studies investigating the role of palliative radiotherapy as well as the consideration of higher radiation dose prescriptions for an improved palliative effect in patients with bone metastasis from HCC [31,32]. In our case, the iliac bone metastasis with a large soft tissue mass was controlled well after a high dose (60 Gy) of radiotherapy over the long-term followup period. Although pathologic fractures occurred at the site of bone destruction by metastatic tumor, radiotherapy was able to maintain the patient’s QoL without pain or difficulty in walking.

SBRT is an established treatment option for early-stage lung cancer [33,34]. In addition, SBRT has also been considered an ablative treatment option for primary or recurrent HCC when curative treatments cannot be safely performed [35,36]. With these promising clinical outcomes, SBRT can also be used as an ablative treatment for pulmonary oligometastasis from HCC. Although there have been few reports discussing the use of SBRT for lung metastasis from HCC, a study of SBRT for lung metastases from colorectal cancer reported very promising local control rates of 88.7% and 70.6% at 1- and 3-years, respectively [37]. In the current case, a small pulmonary metastasis was no longer present at 3 months after SBRT and did not show recurrence on the follow-up CT scans. Therefore, further studies could reveal the potential role of SBRT for lung metastases from HCC in the future. According to the follow-up results of this patient, the metastatic tumor burden was limited in number and organ (socalled oligometastasis) after the primary site was well controlled. The oligometastatic state is considered an intermediate state of tumor spread showing a more indolent disease course. Metastasis-directed therapies for oligometastasis can be effective and promising approaches [38,39], as seen in this patient.

In summary, combined TACE and external beam radiotherapy yielded excellent long-term local tumor control in a patient with recurrent, huge HCC. Despite the extrahepatic recurrences in the bone and lung, salvage radiotherapy is highly effective and allows this patient to maintain his QoL.

Article information Continued